Cellular and Animal Models of Parkinson’s Disease: Rationale into Neuroprotective Effects of Naringenin

Abstract

Parkinson’s disease (PD) is the most common movement condition, marked by motor and nonmotor characteristics. Because the
pathophysiology has not been fully understood, the current therapeutic regimen for PD is primarily symptomatic. Several animal
models have been developed to explore various facets of the disease to understand pathogenesis. The pathophysiology of PD remains
complex, and existing PD therapies appear to be clinically inefficient. Detailed studies on developing novel pharmaceutical alternatives
have shown that natural compounds, such as herbal remedies, extracts, and their secondary metabolites, offer immense potential as
cytoprotective treatments in PD. Recent preclinical studies show that a variety of herbal medicines and their bioactive constituents can
be turned into optimal pharmaceuticals for PD treatment. Naringenin (NAR) is a flavonoid showing neuroprotection in PD pathogenesis.
Here, we focus on the neuroprotective ability of bioactive NAR in cellular and animal models of PD research.